PMID: 16510031Mar 3, 2006Paper

New treatments for nonalcoholic fatty liver disease

Current Gastroenterology Reports
Stephen A Harrison

Abstract

The majority of patients with nonalcoholic fatty liver disease are overweight and obese, lead relatively sedentary lifestyles, and have underlying insulin resistance. Treatment aimed at improving body weight and activity should be the cornerstone of our therapeutic armamentarium in combating this disease. Evidence suggests that diets low in processed carbohydrates and saturated fats with a goal to achieve a 500- to 1000-calorie/day deficit improve insulin sensitivity, reduce serum aminotransferases, and decrease hepatic steatosis. Encouragingly, improvements are seen with as little as a 5% reduction in body weight. Histopathologic parameters of steatohepatitis also appear to improve with weight loss. Antioxidant supplementation, specifically with vitamin E, may be considered as adjunctive therapy. Other antioxidants and the thiazolidinediones (pioglitazone and rosiglitazone) appear to be efficacious, but larger confirmatory studies are needed to ensure they are safe and beneficial in patients with nonalcoholic steatohepatitis. Novel agents such as renin-angiotensin system inhibitors may eventually prove to be efficacious as well. Future treatment for patients failing to achieve weight loss goals is likely to consist of combinat...Continue Reading

References

Mar 1, 1991·Journal of Hepatology·T AndersenP Christoffersen
Feb 1, 1967·The American Journal of Digestive Diseases·P RozentalH J Zimmerman
May 24, 1994·Proceedings of the National Academy of Sciences of the United States of America·G S HotamisligilB M Spiegelman
Jun 1, 1994·The American Journal of Clinical Nutrition·G PaolissoF D'Onofrio
Mar 24, 2000·Pharmacotherapy·A M HeckK A Calis
Nov 18, 2000·The New England Journal of Medicine·H Tilg, A M Diehl
Sep 12, 2001·Hepatology Research : the Official Journal of the Japan Society of Hepatology·T OhishiH Ishii
Sep 25, 2001·The American Journal of Gastroenterology·B A Neuschwander-Tetri
Sep 25, 2001·The American Journal of Gastroenterology·M F AbdelmalekK D Lindor
Oct 5, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·H YoshijiH Fukui
Oct 17, 2001·The Journal of Clinical Investigation·G ZhouD E Moller
Nov 9, 2001·Biochemical and Biophysical Research Communications·V B Bhat, K M Madyastha
May 23, 2002·FEBS Letters·Angelo AzziJean Marc Zingg
Nov 28, 2002·Diabetes·Joseph J SennRobert A Mooney
Jan 24, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Zhiping LiAnna Mae Diehl
Mar 1, 2003·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·G H GoossensM A van Baak
Apr 2, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Giovanni MussoGianfranco Pagano
Jul 29, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Marcelo KugelmasCraig J McClain
Sep 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brent A Neuschwander-TetriBruce R Bacon
Nov 26, 2003·The American Journal of Gastroenterology·Stephen A HarrisonSteven Schenker
Jan 31, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Kittichai PromratJay H Hoofnagle
Feb 28, 2004·Alimentary Pharmacology & Therapeutics·A UygunK Dagalp
Jun 9, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·John B DixonPaul E O'Brien
Jul 1, 2004·Alimentary Pharmacology & Therapeutics·S NairR P Perrillo
Sep 9, 2004·Alimentary Pharmacology & Therapeutics·S A HarrisonP Hayashi
Sep 15, 2004·Circulation·Abhiram Prasad, Arshed A Quyyumi
Sep 24, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Shiro YokohamaKimihide Nakamura
Oct 7, 2004·Journal of Hepatology·Sean W P KoppeRichard M Green
Oct 7, 2004·Clinics in Liver Disease·Stephen A Harrison, Brent A Neuschwander-Tetri
Nov 3, 2004·Trends in Endocrinology and Metabolism : TEM·Joseph L EvansIra D Goldfine
Dec 2, 2004·The American Journal of Gastroenterology·Leon A AdamsKeith D Lindor

❮ Previous
Next ❯

Citations

Sep 1, 2006·Current Treatment Options in Gastroenterology·Eve A Roberts, Jason Yap
May 30, 2008·PPAR Research·Harrihar A Pershadsingh, David M Moore
Jan 19, 2010·Annual Review of Pathology·Dina G TiniakosElizabeth M Brunt
Mar 31, 2007·Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·Ian P J Alwayn, Robert J Porte
Oct 31, 2013·Journal of the American Association of Nurse Practitioners·Lu Ann Cook
Nov 21, 2007·Journal of Hepatology·Jens H Henriksen, Helmer Ring-Larsen

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.